-+ 0.00%
-+ 0.00%
-+ 0.00%

DiaMedica Q1 FY26 net loss widens to $10 million

PUBT·05/06/2026 21:06:57
Listen to the news
DiaMedica Q1 FY26 net loss widens to $10 million
  • DiaMedica Therapeutics posted a net loss of USD 10 million, or USD 0.19 per share, for quarter ended March 31, 2026, versus a net loss of USD 7.7 million, or USD 0.18 per share, a year earlier.
  • R&D spending climbed to USD 8 million from USD 5.7 million, while G&A held flat at USD 2.5 million.
  • Cash, cash equivalents, and investments fell to USD 51.3 million from USD 59.9 million at Dec. 31, 2025; net cash used in operating activities increased to USD 9.1 million from USD 7.1 million.
  • ReMEDy2 Phase 2/3 acute ischemic stroke trial surpassed 70% of required interim enrollment, with interim analysis still planned for 4Q 2026.
  • In preeclampsia, DM199 Phase 2 investigator-sponsored trial Part 1a expansion cohort is enrolling with results expected in 2Q 2026; management reiterated expectation for multiple preeclampsia and fetal growth restriction data readouts through 2027 to inform Phase 3 dose selection.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. DiaMedica Therapeutics Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 202605061630BIZWIRE_USPR_____20260506_BW239545) on May 06, 2026, and is solely responsible for the information contained therein.